Chronic Hyperkalemia in Cardiorenal Patients: Risk Factors, Diagnosis, and New Treatment Options

被引：21

作者：

Di Lullo, Luca ^{[1
]}

Ronco, Claudio ^{[2
]}

Granata, Antonio ^{[3
,4
]}

Paoletti, Ernesto ^{[5
]}

Barbera, Vincenzo ^{[1
]}

Cozzolino, Mario ^{[6
]}

Ravera, Maura ^{[5
]}

Fusaro, Maria ^{[7
]}

Bellasi, Antonio ^{[8
]}

机构：

[1] L Parodi Delfino Hosp, Dept Nephrol & Dialysis, Colleferro, Italy

[2] S Bortolo Hosp, Int Renal Res Inst, Vicenza, Italy

[3] S Giovanni di Dio Hosp, Dept Nephrol & Dialysis, Agrigento, Italy

[4] S Bortolo Hosp, Int Renal Res Inst, Vicenza, Italy

[5] San Martino Hosp, Dept Nephrol & Dialysis, Genoa, Italy

[6] S Paolo Hosp, Dept Hlth Sci, Milan, Italy

[7] Univ Padua, Dept Med, Padua, Italy

[8] St Anna Hosp, ASTT Lariana, Dept Nephrol & Dialysis, Como, Italy

来源：

CARDIORENAL MEDICINE | 2019年 / 9卷 / 01期

关键词：

Hyperkalemia; Chronic kidney disease; Heart failure; Renin-angiotensin-aldosterone system inhibitors; Potassium binder; CHRONIC KIDNEY-DISEASE; SODIUM ZIRCONIUM CYCLOSILICATE; HEART-FAILURE; SERUM POTASSIUM; RENAL-DISEASE; DOUBLE-BLIND; PATIROMER; OUTCOMES; ALDOSTERONE; ASSOCIATION;

D O I：

10.1159/000493395

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Chronic hyperkalemia (HK) is a serious medical condition that often manifests in patients with chronic kidney disease (CKD) and heart failure (HF) leading to poor outcomes and necessitating careful management by cardionephrologists. CKD, HF, diabetes, and renin-angiotensin-aldosterone system inhibitors use is known to induce HK. Current therapeutic options are not optimal, as pointed out by a large number of CKD and HF patients with HK. The following review will focus on the main risk factors for developing HK and also aims to provide a guide for a correct diagnosis and present new approaches to therapy. (C) 2018 S. Karger AG, Basel

引用

页码：8 / 21

页数：14

共 62 条

[1] Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000, cases in the Acute Decompensated Heart Failure National Registry (ADHERE) [J].

Adams, KF ;

Fonarow, GC ;

Emerman, CL ;

LeJemtel, TH ;

Costanzo, MR ;

Abraham, WT ;

Berkowitz, RL ;

Galvao, M ;

Horton, DP .

AMERICAN HEART JOURNAL, 2005, 149 (02) :209-216

[2] Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors [J].

Ahuja, TS ;

Freeman, D ;

Mahnken, JD ;

Agraharkar, M ;

Siddiqui, M ;

Memon, A .

AMERICAN JOURNAL OF NEPHROLOGY, 2000, 20 (04) :268-272

[3] HYPERKALEMIA AND RENAL-INSUFFICIENCY - ROLE OF SELECTIVE ALDOSTERONE DEFICIENCY AND TUBULAR UNRESPONSIVENESS TO ALDOSTERONE [J].

ARRUDA, JAL ;

BATLLE, DC ;

SEHY, JT ;

ROSEMAN, MK ;

BARONOWSKI, RL ;

KURTZMAN, NA .

AMERICAN JOURNAL OF NEPHROLOGY, 1981, 1 (3-4) :160-167

[4] A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient [J].

Ash, Stephen R. ;

Singh, Bhupinder ;

Lavin, Philip T. ;

Stavros, Fiona ;

Rasmussen, Henrik S. .

KIDNEY INTERNATIONAL, 2015, 88 (02) :404-411

[5] Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease The AMETHYST-DN Randomized Clinical Trial [J].

Bakris, George L. ;

Pitt, Bertram ;

Weir, Matthew R. ;

Freeman, Mason W. ;

Mayo, Martha R. ;

Garza, Dahlia ;

Stasiv, Yuri ;

Zawadzki, Rezi ;

Berman, Lance ;

Bushinsky, David A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (02) :151-161

[6] The Cost of Hyperkalemia in the United States [J].

Betts, Keith A. ;

Woolley, J. Michael ;

Mu, Fan ;

Xiang, Cheryl ;

Tang, Wenxi ;

Wu, Eric Q. .

KIDNEY INTERNATIONAL REPORTS, 2018, 3 (02) :385-393

[7] EXTRA-RENAL POTASSIUM HOMEOSTASIS [J].

BIA, MJ ;

DEFRONZO, RA .

AMERICAN JOURNAL OF PHYSIOLOGY, 1981, 240 (04) :F257-F268

[8] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[9] Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia [J].

Bushinsky, David A. ;

Williams, Gordon H. ;

Pitt, Bertram ;

Weir, Matthew R. ;

Freeman, Mason W. ;

Garza, Dahlia ;

Stasiv, Yuri ;

Li, Elizabeth ;

Berman, Lance ;

Bakris, George L. .

KIDNEY INTERNATIONAL, 2015, 88 (06) :1427-1433

[10]

Cada Dennis J, 2013, Hosp Pharm, V48, P855, DOI 10.1310/hpj4810-855

← 1 2 3 4 5 6 7 →